Treakisym to Be Used as a Pre-Treatment To CAR-T Therapy
Announcement – Symbio Pharmaceuticals (4582 JP) on September 27, 2018, announced that it has filed a partial change application for marketing...
732 Views
Growth Drivers on Track – Operational Turnaround Expected in 2021
We reiterate our “Overweight” rating on the stock post 1H FY18 (YE Dec-18) earnings1H FY18 Results Highlights Symbio reported an increase in 1H...
376 Views
SymBio Pharmaceuticals - Self-commercialization gains favor
With the lifecycle of Treakisym extended through the in-licensing of liquid formulations from Eagle in 2017, SymBio is refining its plans to...
42 Views
SymBio Pharmaceuticals - Self-commercialisation gains favour
With the lifecycle of Treakisym extended through the in-licensing of liquid formulations from Eagle in 2017, SymBio is refining its plans to...
48 Views
Symbio Pharma (4582 JP) - Gross Margin Expansion Led Operational Turnaround in 2021
2020 – an inflection point for Symbio Treakisym (bendamustine), Symbio’s only revenue driver currently, is marketed by Eisai in Japan for r/r NHL....
140 Views